© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
October 14, 2016
William J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
September 25, 2016
Hope S. Rugo, MD, discusses immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.
September 24, 2016
Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.
September 23, 2016
William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.